Dexanabinol in Patients With Brain Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

September 30, 2015

Study Completion Date

July 31, 2017

Conditions
Brain Cancer
Interventions
DRUG

Dexanabinol

"Dexanabinol: intravenous infusion over 3 hours, weekly (i.e., Day 1, 8, 15 and 22 of a 28-day cycle)~Nine dosing cohorts are planned, with the option to enroll additional cohorts based on safety and PK data.~Dose Level 1: 2 mg/kg~Dose Level 2: 4 mg/kg~Dose Level 3: 8 mg/kg~Dose Level 4: 16 mg/kg~Dose Level 5: 24 mg/kg~Dose Level 6: 28 mg/kg~Dose Level 7: 36 mg/kg~Dose Level 8: 40 mg/kg~Dose Level 9: 44 mg/kg"

Trial Locations (1)

92093-0698

Moores UCSD Cancer Center, La Jolla

All Listed Sponsors
collaborator

e-Therapeutics PLC

INDUSTRY

lead

Santosh Kesari, M.D., Ph.D.

OTHER

NCT01654497 - Dexanabinol in Patients With Brain Cancer | Biotech Hunter | Biotech Hunter